skip to Main Content
  • This page as PDF
October 25, 2018 12:30 - 1:30 PM ET

Drug Pricing Policy: What’s on the Horizon?


Avalere experts examine the current drug pricing policy landscape and what potential changes stakeholders should prepare for.

The recent proposal by the administration to require manufacturers to disclose list prices in direct-to-consumer (DTC) advertising is the latest in a wave of recent policy activity focused on prescription drugs at the state and federal levels. This includes noteworthy activity such as allowing indication-based formularies in Part D and step therapy in Medicare Advantage, soliciting feedback on new models to manage Part B drugs, and state efforts to manage Medicaid drug costs. So what’s next?

Avalere experts recap recent policy action and preview future policy activity focused on prescription medications. This webinar provides insights into potential changes, market impacts, and considerations for healthcare stakeholders.

Topics covered:

  • Potential action on management of physician-administered drugs
  • Manufacturer rebates
  • State management of drugs in Medicaid
  • Part D reforms


Elizabeth Carpenter , Head of Advisory Services, Policy

Elizabeth Carpenter leads the Policy Practice at Avalere.

Matt Brow , President & General Manager - Pharmacy, Life Sciences & Advisory, Avalere Executive

Matt Brow is president and general manager of Avalere Health, Inovalon's data-driven advisory business.

Miryam Frieder , Practice Director, Policy

Miryam Frieder leads strategic client engagements focused on the drug pricing policy environment, rebate reform models, and Medicare Part D. Miryam advises clients on assessing the impact of the evolving policy landscape to inform business decisions and policy engagement strategies.

Lance Grady , Managing Director, Commercialization & Regulatory Strategy

Lance Grady devises commercialization strategies focused on value, access, and reimbursement.

Milena Sullivan , Principal, Policy

Milena Sullivan advises life sciences clients on the impact of the evolving healthcare policy landscape on their commercial, access, and advocacy priorities.

From beginning to end, our team synergy
produces measurable results. Let's work together.
Back To Top